期刊
MOLECULAR ENDOCRINOLOGY
卷 25, 期 11, 页码 1835-1848出版社
OXFORD UNIV PRESS INC
DOI: 10.1210/me.2011-1197
关键词
-
资金
- Austrian Science Fund [P18723]
- Jubilaumsfonds of the Austrian National Bank
- Lanyar Stiftung Graz
- Medical University of Graz, Graz, Austria
- BaCa Visiting Scientists program
- European Molecular Biology Organization
- Medical University of Graz
- Austrian Government
- Medical Research Council
- Spanish Ministry of Science and Innovation
- Spanish Association Against Cancer
- Mutua Madrilena
- GW
- Otsuka Pharmaceuticals
- 'Acciones Integradas' grant between Austria and Spain
- Austrian Science Fund (FWF) [P18723] Funding Source: Austrian Science Fund (FWF)
Emerging data suggest that off-target cannabinoid effects may be mediated via novel seven-transmembrane spanning/G protein-coupled receptors. Due to its cannabinoid sensitivity, the G protein-coupled receptor 55 (GPR55) was recently proposed as a candidate; however, GPR55 is phylogenetically distinct from the traditional cannabinoid receptors, and the conflicting pharmacology, signaling, and functional data have prevented its classification as a novel cannabinoid receptor. Indeed, the most consistent and potent agonist to date is the noncannabinoid lysophospholipid, lysophosphatidylinositol. Here we present new human GPR55 mRNA expression data, providing supportive evidence of GPR55 expression in a vast array of tissues and cell types. Moreover, we summarize major recent developments in GPR55 research and aim to update the reader in the rapidly expanding fields of GPR55 pharmacology, physiology, and pathology. (Molecular Endocrinology 25: 1835-1848, 2011)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据